S P Krotneva1, A Ramjaun2, K E Reidel1, T Eguale3, N Trabulsi4, N Mayo5, R Tamblyn6, A N Meguerditchian7. 1. Clinical and Health Informatics Research Group, McGill University, Montreal, QC. 2. Clinical and Health Informatics Research Group, McGill University, Montreal, QC. ; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC. 3. Clinical and Health Informatics Research Group, McGill University, Montreal, QC. ; Department of Medicine, McGill University, Montreal, QC. 4. Department of Surgery, McGill University, Montreal, QC. ; Department of Surgery, King Abdul-Aziz University, Saudi Arabia. 5. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC. ; Department of Medicine, McGill University, Montreal, QC. ; School of Physical and Occupational Therapy, McGill University, Montreal, QC. 6. Clinical and Health Informatics Research Group, McGill University, Montreal, QC. ; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC. ; Department of Medicine, McGill University, Montreal, QC. 7. Clinical and Health Informatics Research Group, McGill University, Montreal, QC. ; Department of Oncology, McGill University, Montreal, QC.
Abstract
PURPOSE: Breast cancer treatment guidelines state that radiotherapy (rt) can reasonably be omitted in selected women 70 years of age and older if they take adjuvant endocrine therapy (aet) for 5 years. We aimed to assess persistence and adherence to aet in women 70 years of age and older, and to examine differences between rt receivers and non-receivers. METHODS: Quebec's medical service and pharmacy claims databases were used to identify seniors undergoing breast-conserving surgery (1998-2005) and initiating aet. Cox proportional hazards models were used to identify predictors of aet non-persistence. RESULTS: Of 3180 women who initiated aet (mean age: 77.5 years), 28% did not receive rt. During the subsequent 5 years, 32% of patients who initiated aet did not persist, 2% filled only a single prescription, and 22% switched medications. Compared with rt receivers, non-receivers discontinued more often (35.5% vs. 30.1%) and earlier (1.4 years vs. 1.6 years). They also became nonadherent earlier (medication possession ratio < 80% at year 3 vs. at year 5). Predictors of nonpersistence included rt omission [hazard ratio (hr): 1.26; 95% confidence interval (ci): 1.09 to 1.46]; age (hr per decade increase: 1.15; 95% ci: 1.01 to 1.31); new medications (hr per medication: 1.01; 95% ci: 1.00 to 1.02); and hospitalizations during aet, (hr per hospitalization: 1.08; 95% ci: 1.05 to 1.11). In a subanalysis of rt non-receivers, significant predictors included hospitalizations (hr: 1.07; 95% ci: 1.02 to 1.12) and medications at aet start (hr: 0.94; 95% ci: 0.91 to 0.97). CONCLUSIONS: Suboptimal use of aet was observed in at least one third of women. In rt non-receivers, aet use was worse than it was in rt receivers. Initiation of new medications and hospitalizations increased the risk of non-persistence.
PURPOSE:Breast cancer treatment guidelines state that radiotherapy (rt) can reasonably be omitted in selected women 70 years of age and older if they take adjuvant endocrine therapy (aet) for 5 years. We aimed to assess persistence and adherence to aet in women 70 years of age and older, and to examine differences between rt receivers and non-receivers. METHODS: Quebec's medical service and pharmacy claims databases were used to identify seniors undergoing breast-conserving surgery (1998-2005) and initiating aet. Cox proportional hazards models were used to identify predictors of aet non-persistence. RESULTS: Of 3180 women who initiated aet (mean age: 77.5 years), 28% did not receive rt. During the subsequent 5 years, 32% of patients who initiated aet did not persist, 2% filled only a single prescription, and 22% switched medications. Compared with rt receivers, non-receivers discontinued more often (35.5% vs. 30.1%) and earlier (1.4 years vs. 1.6 years). They also became nonadherent earlier (medication possession ratio < 80% at year 3 vs. at year 5). Predictors of nonpersistence included rt omission [hazard ratio (hr): 1.26; 95% confidence interval (ci): 1.09 to 1.46]; age (hr per decade increase: 1.15; 95% ci: 1.01 to 1.31); new medications (hr per medication: 1.01; 95% ci: 1.00 to 1.02); and hospitalizations during aet, (hr per hospitalization: 1.08; 95% ci: 1.05 to 1.11). In a subanalysis of rt non-receivers, significant predictors included hospitalizations (hr: 1.07; 95% ci: 1.02 to 1.12) and medications at aet start (hr: 0.94; 95% ci: 0.91 to 0.97). CONCLUSIONS: Suboptimal use of aet was observed in at least one third of women. In rt non-receivers, aet use was worse than it was in rt receivers. Initiation of new medications and hospitalizations increased the risk of non-persistence.
Entities:
Keywords:
Adjuvant endocrine therapy; adherence; breast cancer; persistence; radiotherapy; seniors
Authors: Paul D James; Russell Wilkins; Allan S Detsky; Peter Tugwell; Douglas G Manuel Journal: J Epidemiol Community Health Date: 2007-04 Impact factor: 3.710
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Aliza K Fink; Jerry Gurwitz; William Rakowski; Edward Guadagnoli; Rebecca A Silliman Journal: J Clin Oncol Date: 2004-08-15 Impact factor: 44.544
Authors: Joyce A Cramer; Anuja Roy; Anita Burrell; Carol J Fairchild; Mahesh J Fuldeore; Daniel A Ollendorf; Peter K Wong Journal: Value Health Date: 2008 Jan-Feb Impact factor: 5.725
Authors: Timothy L Lash; Matthew P Fox; Jennifer L Westrup; Aliza K Fink; Rebecca A Silliman Journal: Breast Cancer Res Treat Date: 2006-03-16 Impact factor: 4.872
Authors: Ari Meguerditchian; Robyn Tamblyn; Sarkis Meterissian; Susan Law; Jaroslav Prchal; Nancy Winslade; Donna Stern Journal: JMIR Res Protoc Date: 2016-11-07